RA-002

RA-002 is an investigational therapeutic candidate developed by Red Arrow Therapeutics, currently in the discovery to preclinical stage of development. It is built upon the company's proprietary Nanopolymer Cytokine Micelle (NCM) platform technology. This platform is designed to encapsulate cytokine payloads within biocompatible polymeric micelles, aiming to enhance the pharmacokinetic profile, stability, and safety of cytokine therapies by minimizing systemic exposure and off-target effects. While the specific cytokine payload and primary disease indications for RA-002 have not been publicly disclosed by the developer, the program leverages the same delivery architecture as the company's lead program, RA-001.